NASDAQ:NUWE Nuwellis (NUWE) Stock Price, News & Analysis $0.49 -0.11 (-17.85%) Closing price 04:00 PM EasternExtended Trading$0.50 +0.02 (+3.81%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nuwellis Stock (NASDAQ:NUWE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nuwellis alerts:Sign Up Key Stats Today's Range$0.48▼$0.6150-Day Range$0.49▼$1.2352-Week Range$0.48▼$34.02Volume507,996 shsAverage Volume140,621 shsMarket Capitalization$1.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays. The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting. This technology is used in hospitals, specialty renal centers and other acute care facilities. The system’s design emphasizes ease of use for clinicians, with automated control features and real‐time monitoring that support individualized treatment plans and help mitigate the risks associated with rapid fluid shifts. Originally founded as Renal Solutions in 2005, the company adopted the Nuwellis name in 2016 to reflect a broader commitment to advancing fluid management therapies. Headquartered in Plymouth, Minnesota, Nuwellis holds both FDA clearance in the United States and CE Mark approval for distribution across Europe. Its sales and distribution network serves acute care hospitals and renal clinics across North America and select international markets. Nuwellis continues to invest in research and development aimed at expanding the clinical applications of its ultrafiltration technology. The company’s leadership team includes seasoned executives with extensive experience in medical devices and healthcare innovation. Ongoing efforts focus on regulatory approvals, commercial partnerships and clinical studies to validate new indications and broaden access to its therapies worldwide.AI Generated. May Contain Errors. Read More Nuwellis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreNUWE MarketRank™: Nuwellis scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingNuwellis has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageNuwellis has only been the subject of 1 research reports in the past 90 days.Read more about Nuwellis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuwellis is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuwellis is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuwellis has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Nuwellis' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.34% of the float of Nuwellis has been sold short.Short Interest Ratio / Days to CoverNuwellis has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nuwellis has recently decreased by 49.65%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuwellis does not currently pay a dividend.Dividend GrowthNuwellis does not have a long track record of dividend growth. News and Social Media3.4 / 5News SentimentN/A News SentimentNuwellis has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nuwellis this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Nuwellis to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nuwellis insiders have not sold or bought any company stock.Percentage Held by Insiders1.60% of the stock of Nuwellis is held by insiders.Percentage Held by Institutions3.13% of the stock of Nuwellis is held by institutions.Read more about Nuwellis' insider trading history. Receive NUWE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuwellis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NUWE Stock News HeadlinesAnalysts Have Conflicting Sentiments on These Healthcare Companies: Altimmune (ALT), Nuwellis (NUWE) and Siegfried Holding AG (OtherSGFEF)May 15, 2026 | theglobeandmail.comNuwellis Announces Successful Completion of FDA Pre-Submission 510(k) Meeting to Expand Aquadex LabelMay 14, 2026 | globenewswire.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.June 3 at 1:00 AM | Weiss Ratings (Ad)Nuwellis, Inc. (NUWE) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comNuwellis, Inc. Announces First Quarter 2026 Financial ResultsMay 12, 2026 | globenewswire.comNuwellis, Inc. To Announce First Quarter 2026 Financial Results on May 12, 2026May 5, 2026 | globenewswire.comNuwellis Highlights Case Study Featuring Precision Ultrafiltration Therapy in Pediatric Cardiorenal Care at ISHLT 2026 Annual MeetingApril 29, 2026 | globenewswire.comNuwellis Announces Receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for Innovative Dual Lumen Midline Catheter TechnologyApril 28, 2026 | globenewswire.comSee More Headlines NUWE Stock Analysis - Frequently Asked Questions How have NUWE shares performed this year? Nuwellis' stock was trading at $1.74 at the beginning of 2026. Since then, NUWE stock has decreased by 72.1% and is now trading at $0.4855. How were Nuwellis' earnings last quarter? Nuwellis, Inc. (NASDAQ:NUWE) released its quarterly earnings data on Tuesday, May, 12th. The company reported ($2.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by $1.09. The company earned $2.40 million during the quarter, compared to analyst estimates of $2.09 million. Nuwellis had a negative net margin of 214.90% and a negative trailing twelve-month return on equity of 32,351.83%. Read the conference call transcript. When did Nuwellis' stock split? Shares of Nuwellis reverse split before market open on Friday, June 28th 2024.The 1-35 reverse split was announced on Friday, June 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Nuwellis? Shares of NUWE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nuwellis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuwellis investors own include Verb Technology (VERB), TransCode Therapeutics (RNAZ), Exela Technologies (XELA), AMC Entertainment (AMC), BIOLASE (BIOL) and Company Calendar Last Earnings5/12/2026Today6/03/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 NUWE's financial health is in the Yellow zone, according to TradeSmith. NUWE has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:NUWE CIK1506492 Webwww.nuwellis.com Phone(952) 345-4200FaxN/AEmployees70Year FoundedN/AProfitability EPS (Trailing Twelve Months)($64.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.52 million Net Margins-214.90% Pretax Margin-217.17% Return on Equity-32,351.83% Return on Assets-249.08% Debt Debt-to-Equity RatioN/A Current Ratio1.56 Quick Ratio1.09 Sales & Book Value Annual Sales$8.27 million Price / Sales0.16 Cash FlowN/A Price / Cash FlowN/A Book Value$1.58 per share Price / Book0.31Miscellaneous Outstanding Shares2,680,000Free Float2,638,000Market Cap$1.30 million OptionableNot Optionable Beta0.18 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:NUWE) was last updated on 6/3/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredElon’s AI supercomputer just went live. Here’s my #1 stock.Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuwellis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuwellis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
